The reference ranges for blood copper (Cu) concentration used by SAC and the UK Veterinary Laboratories Agency have been developed for use with plasma only. Copper sequestration into the clot, primarily in the form of caeruloplasmin, means that serum Cu concentrations are significantly lower than plasma Cu concentrations in the same animals. Serum Cu is commonly used as a surrogate for plasma Cu by applying a proportional conversion factor. However the results of these two studies, which involved a total of 104 pairs of serum and Cu samples from 84 Holstein cattle in one herd, suggest that serum Cu concentrations should not be used in this way. First, the reduction in Cu concentration during clotting was unrelated to initial plasma concentration (varying from 8-59%), which suggests that using a proportional conversion factor is incorrect. Secondly, the correlation between plasma and serum Cu concentration, while significant, was relatively low (r2 proportional 0.6), with the individual variation in Cu loss during clotting ranging from 1.5 to 10.8 micromol/L (mean 4.9 micromol/L). Although this study was undertaken using samples from normocupraemic lactating Holstein cattle in one herd, the data strongly suggest that plasma rather than serum Cu should be used to estimate Cu status unless the laboratory used has developed a reliable serum reference range. We also found that factors other than plasma Cu concentration had a significant effect on loss of Cu during the clotting process. However, no significant effect on the loss of Cu during clotting or by varying the incubation/storage time and temperature of bloods prior to clot removal was noted, nor was there any significant effect of age or Cu intake. Furthermore, when the loss of Cu during clotting was examined in the same heifers at two different timepoints, no correlation between the results was found. Further research is required to establish the factors that affect the loss of Cu during clotting.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.tvjl.2004.11.008 | DOI Listing |
Acta Biomater
January 2025
State Key Laboratory of High Performance Ceramics and Superfine Microstructure Shanghai Institute of Ceramics, Chinese Academy of Sciences, 1295 Dingxi Road, Shanghai 200050, P.R. China; Center of Materials Science and Optoelectronics Engineering, University of Chinese Academy of Sciences, 19A Yuquan Road, Beijing 100049, P. R. China. Electronic address:
Non-compressible hemostasis and promoting tissue healing are important in soft tissue trauma repair. Inorganic aerogels show superior performance in rapid hemostasis or promoting tissue healing, but simultaneously promoting non-compressive hemostasis and soft tissue healing still remains a challenge. Herein, SiO-based inorganic nanofiber aerogels (M@SiO, M=Ca, Mg, and Sr) were prepared by freeze-drying the mixture of bioactive silicates-deposited SiO nanofibers and SiO sol.
View Article and Find Full Text PDFAdv Healthc Mater
January 2025
Antimicrobial Research Laboratory, New Chemistry Unit, Jawaharlal Nehru Centre for Advanced Scientific Research, Jakkur, Bengaluru, Karnataka, 560064, India.
Uncontrollable haemorrhage and associated microbial contamination in the battlefield and civilian injuries pose a tremendous threat to healthcare professionals. Such traumatic wounds often necessitate an effective point-of-care solution to prevent the consequent morbidity owing to blood loss or haemorrhage. However, developing superior hemostatic materials with anti-infective properties remains a challenge.
View Article and Find Full Text PDFNephrology (Carlton)
January 2025
Transplant & Comprehensive Liver Center, Hartford, Connecticut, USA.
Aim: Henoch-Schönlein purpura (HSP) nephritis leads to end-stage renal disease (ESRD) in upto 3% of cases, necessitating kidney transplantation (KT). This study compared graft and patient survival outcomes between HSP and non-HSP KT recipients and identified factors associated with HSP recurrence.
Methods: Data from the Scientific Registry of Transplant Recipients (SRTR) were analysed for adult and paediatric KT patients listed between January 2005 and April 2021.
Arq Bras Cir Dig
January 2025
Department of Gastroenterology, Hospital das Clinicas, Faculty of Medicine, Universidade de São Paulo - São Paulo (SP), Brazil.
Background: Blood loss during liver transplantation (LT) remains a major concern associated with increased morbidity and reduced patient and graft survival. The high complexity of the procedure associated with the multifaceted origin of the bleeding urges early identification of high-risk patients and proper monitoring of hemostasis disorders in order to improve results. The accuracy of international normalized ratio (INR) and activated partial thromboplastin time (aPTT) to evaluate coagulation status in cirrhotic patients has been doubted.
View Article and Find Full Text PDFJ Dermatol
January 2025
Pfizer, Groton, Connecticut, USA.
Ritlecitinib is an oral Janus kinase 3/tyrosine kinase expressed in hepatocellular carcinoma (JAK3/TEC) family kinase inhibitor approved for the treatment of severe alopecia areata (AA). Benefit-risk profiles of two doses of ritlecitinib (50 mg vs 30 mg once daily) were evaluated by integrating patient preferences and clinical efficacy and safety estimates for ritlecitinib. A discrete-choice experiment (DCE) was utilized to elicit preferences for benefit and safety attributes of systemic AA treatments.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!